| Literature DB >> 17071117 |
Sharon Bingham1, Paul J Beswick, David E Blum, Norman M Gray, Iain P Chessell.
Abstract
Cycloxygenase (COX) pathways have long been targeted for the treatment of inflammatory pain, initially through the use of NSAIDs. With the demonstration of two major COX isoforms, COX-1 and COX-2, involved in the production of prostanoids, but with different distribution and regulation, selective COX-2 inhibitors have been developed. This review covers factors influencing COX enzyme activity, the role of their products in the development and maintenance of pain and discusses recent safety concerns of COX-2 inhibitors.Entities:
Mesh：
Substances：
Year: 2006 PMID： 17071117 DOI： 10.1016/j.semcdb.2006.09.001
Source DB: PubMed Journal: Semin Cell Dev Biol ISSN： 1084-9521 Impact factor: 7.727